Oridonin Suppresses Proliferation of Human Ovarian Cancer Cells via Blockage of mTOR Signaling

  • Xia, Rong (Department of Transfusion, Huashan Hospital, Fudan University) ;
  • Chen, Sun-Xiao (Changzheng Hospital, Second Military Medical University) ;
  • Qin, Qin (Department of Laboratory Diagnosis, Changhai Hospital, Second Military Medical University) ;
  • Chen, Yan (Department of Laboratory Diagnosis, Changhai Hospital, Second Military Medical University) ;
  • Zhang, Wei-Wei (Department of Laboratory Diagnosis, Changhai Hospital, Second Military Medical University) ;
  • Zhu, Rong-Rong (Department of Laboratory Diagnosis, Changhai Hospital, Second Military Medical University) ;
  • Deng, An-Mei (Department of Laboratory Diagnosis, Changhai Hospital, Second Military Medical University)
  • Published : 2016.03.07


Oridonin, an ent-kaurane diterpenoid compound isolated from the traditional Chinese herb Rabdosia rubescens, has shown various pharmacological and physiological effects such as anti-tumor, anti-bacterial, and anti-inflammatory properties. However, the effect of oridonin on human ovarian cancer cell lines has not been determined. In this study, we demonstrated that oridonin inhibited ovarian cancer cell proliferation, migration and invasion in a dose-dependent manner. Furthermore, we showed oridonin inhibited tumor growth of ovarian cancer cells (SKOV3) in vivo. We then assessed mechanisms and found that oridonin specifically abrogated the phosphorylation/activation of mTOR signaling. In summary, our results indicate that oridonin is a potential inhibitor of ovarian cancer by blocking the mTOR signaling pathway.


Supported by : National Science Foundation of China


  1. Assaf AM, Haddadin RN, Aldouri NA, et al (2013). Anti-cancer, anti-inflammatory and anti-microbial activities of plant extracts used against hematological tumors in traditional medicine of Jordan. J Ethnopharmacol, 145, 728-36.
  2. Bu HQ, Liu DL, Wei WT, et al (2014). Oridonin induces apoptosis in SW1990 pancreatic cancer cells via p53- and caspase-dependent induction of p38 MAPK. Oncol Rep, 31, 975-82.
  3. Eheman CR, Peipins L, Wynn M, et al (2006). Development of a public health research program for ovarian cancer. J Womens Health (Larchmt), 15, 339-45.
  4. Guo W, Zheng P, Zhang J, et al (2013). Oridonin suppresses transplant rejection by depleting T cells from the periphery. Int Immunopharmacol, 17, 1148-54.
  5. Husseinzadeh N and Husseinzadeh HD (2014). mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: A critical review. Gynecol Oncol,
  6. Konkimalla VB and Efferth T (2008). Anti-cancer natural product library from traditional chinese medicine. Comb Chem High Throughput Screen, 11,7-15.
  7. Li CY, Huang WF, Wang QL, et al (2012). Crocetin induces cytotoxicity in colon cancer cells via p53-independent mechanisms. Asian Pac J Cancer Prev, 13, 3757-61.
  8. Miao L, Xiong X, Lin Y, et al (2014). miR-203 inhibits tumor cell migration and invasion via caveolin-1 in pancreatic cancer cells. Oncol Lett, 7, 658-62.
  9. Pollack LA, Rowland JH, Crammer C, et al (2009). Introduction:charting the landscape of cancer survivors' health-related outcomes and care. Cancer, 115, 4265-9.
  10. Ren KK, Wang HZ, Xie LP, et al (2006). The effects of oridonin on cell growth, cell cycle, cell migration and differentiation in melanoma cells. J Ethnopharmacol, 103, 176-80.
  11. Serkies K, Wegrzynowicz E and Jassem J (2011). Paclitaxel and cisplatin chemotherapy for ovarian cancer during pregnancy:case report and review of the literature. Arch Gynecol Obstet, 283, 97-100.
  12. Wang CD, Yuan CF, Bu YQ, et al (2014). Fangchinoline inhibits cell proliferation via Akt/GSK-3beta/ cyclin D1 signaling and induces apoptosis in MDA-MB-231 breast cancer cells. Asian Pac J Cancer Prev, 15, 769-73.
  13. Wang H, Ye Y and Yu ZL (2014). Proteomic and functional analyses demonstrate the involvement of oxidative stress in the anticancer activities of oridonin in HepG2 cells. Oncol Rep, 31, 2165-72
  14. Wang S, Zhong Z, Wan J, et al (2013). Oridonin induces apoptosis, inhibits migration and invasion on highlymetastatic human breast cancer cells. Am J Chin Med, 41,177-96.
  15. Xu WT, Yang Z, Lu NH (2014). Roles of PTEN (phosphatase and tensin homolog) in gastric cancer development and progression. Asian Pac J Cancer Prev, 15, 17-24.
  16. Yi T, Yi Z, Cho SG, et al (2008). Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res, 68, 1843-50.
  17. Zagouri F, Sergentanis TN, Chrysikos D, et al (2012). mTOR inhibitors in breast cancer: a systematic review. Gynecol Oncol, 127, 662-72.
  18. Zhang T, Qu S, Shi Q, et al (2014). Evodiamine induces apoptosis and enhances TRAIL-induced apoptosis in human bladder cancer cells through mTOR/S6K1-mediated downregulation of Mcl-1. Int J Mol Sci, 15, 3154-71.
  19. Zhao H, Wang L, Wei R, et al (2014). Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway. Diabetes Obes Metab, 16, 850-60

Cited by

  1. Oridonin induces apoptosis in human oral cancer cells via phosphorylation of histone H2AX vol.125, pp.6, 2017,
  2. PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer vol.8, pp.1, 2018,